NYSE$DVA

DaVita HealthCare Partners Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

DaVita reported solid financial growth in Q4 2024, with higher revenue and improved profitability.

DaVita Inc. delivered strong Q4 2024 results, with revenue reaching $3.295 billion, a 4.73% increase YoY. Operating margin expanded to 17.2%, reflecting cost efficiencies and higher reimbursement rates. Adjusted EPS was $2.24, while net income rose significantly to $259.33 million.

  • Revenue grew 4.73% YoY to $3.295 billion.
  • Operating income increased to $565 million, with a 17.2% margin.
  • Adjusted EPS of $2.24 reflected improved profitability.
  • Strong performance in Integrated Kidney Care with 48.2% YoY growth.

Headline financials

Total Revenue

$3.29B

Previous: $3.15B+4.7%
EPS (adj)

$2.24

Previous: $1.87+19.8%
U.S. Dialysis Treatments

7.3M

No prior period
U.S. Dialysis Treatment Days

79.3

No prior period
U.S. Dialysis Avg Treatments per Day

91.8K

No prior period
U.S. Dialysis Avg Revenue per Treatment

$395.87

No prior period
Capital Expenditures

-$171M

Previous: -$159M-7.3%
Net Income

$259M

Previous: $231M+12.5%
Operating Income

$565M

Previous: $390M+45.0%
Gross Profit

$3.29B

Previous: $812M+305.7%

Revenue & EPS history

DaVita · Revenue · Quarterly

$3.29B

Q4 2024+4.7%vs Q4 2023
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

DaVita · $3.14B total across 3 segments · Q3 2023

  • U.S. Dialysis Patient Services
    $2.79B+3.0%
  • International Dialysis Patient Service
    $200M+14.3%
  • Integrated Kidney Care
    $158M+81.6%

Forward guidance

DaVita expects continued revenue growth and profitability improvements in 2025, with adjusted EPS guidance between $10.20 and $11.30.

Tailwinds

  • 2025 adjusted operating income guidance of $2.01B - $2.16B.
  • Free cash flow expected to be between $1.00B - $1.25B.
  • Continued growth in risk-based Integrated Kidney Care segment.
  • Strong cost controls and efficiency initiatives improving margins.
  • Ongoing share repurchase program supporting EPS growth.

Headwinds

  • Declining treatment volume due to lower patient census.
  • Increased costs from center closures and restructuring.
  • Higher general and administrative expenses impacting profitability.
  • Potential reimbursement rate changes affecting revenue.
  • Rising labor and insurance costs adding operational pressures.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+0.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+1.6%

Avg return

30 days after

54%

39 / 72 earnings

Positive

+14.7%

Q3 2019

Best reaction

-24.5%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.6%+22.2%+22.4%
Q4 2025+11.0%+26.7%+34.9%
Q3 2025-6.0%-5.2%-5.4%
Q1 2025-0.2%+0.7%-4.9%
Q4 2024-11.1%-12.5%-19.0%
Q3 2024-10.1%-9.8%+5.5%
Q2 2024-1.1%+3.6%+9.8%
Q1 2024-3.8%-1.5%+5.3%
Q4 2023+8.0%+6.9%+19.0%
Q3 2023+7.4%+5.1%+33.9%
Q2 2023+6.7%+8.6%+1.0%
Q1 2023+13.8%+5.9%+13.7%
Q4 2022-0.3%-0.3%-8.4%
Q3 2022-24.5%-27.9%-23.6%
Q2 2022+2.7%+1.8%+1.3%
Q1 2022-7.1%-5.0%-12.7%
Q4 2021-1.2%+3.5%-2.6%
Q3 2021-6.9%-6.2%-12.3%
Q2 2021+10.2%+9.7%+10.0%
Q1 2021+2.8%+8.9%+6.0%
Q4 2020-7.4%-8.1%-4.4%
Q3 2020-0.0%+7.7%+27.4%
Q2 2020-4.3%-8.5%-4.8%
Q1 2020+9.6%+7.5%+9.7%
Q4 2019+8.8%+5.7%-8.0%
Q3 2019+14.7%+13.6%+17.9%
Q2 2019+0.4%-1.5%-5.8%
Q1 2019-10.4%-9.8%-19.4%
Q4 2018+1.3%+3.0%-6.7%
Q3 2018+1.3%-1.5%-14.9%
Q2 2018+5.4%+3.9%-1.4%
Q1 2018+4.7%+1.2%+5.9%
Q4 2017+1.8%+0.3%-5.4%
Q3 2017-8.5%-7.4%+13.0%
Q2 2017-9.8%-10.9%-9.6%
Q1 2017-3.8%-5.3%-2.4%
Q4 2016+3.2%+6.2%+4.5%
Q3 2016+1.1%+0.1%+11.1%
Q2 2016-6.0%-10.1%-16.4%
Q1 2016+2.9%
Q4 2015-1.7%
Q3 2015-0.9%
Q2 2015+1.0%
Q1 2015-1.1%
Q4 2014-3.8%
Q3 2014-3.9%
Q2 2014+0.1%
Q1 2014-2.8%
Q4 2013+3.9%
Q3 2013-3.0%
Q2 2013-2.9%
Q1 2013+9.4%
Q4 2012-1.1%
Q3 2012+1.4%
Q2 2012-1.1%
Q1 2012-4.9%
Q4 2011+0.3%
Q3 2011+0.8%
Q2 2011-0.2%
Q1 2011+2.9%
Q4 2010+2.4%
Q3 2010-0.4%
Q2 2010+3.3%
Q1 2009+1.1%
Q1 2010+0.3%
Q4 2009-0.1%
Q3 2009+0.1%
Q3 2008+0.1%
Q2 2008+4.6%
Q4 2008+4.6%
Q2 2009+4.6%
Q4 2007+4.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro